The oral semaglutide brand name question most people get wrong

You searched for oral semaglutide, here is what you actually found

Picture this: you've spent twenty minutes on a search engine trying to work out whether "oral semaglutide" refers to Wegovy tablets, Rybelsus, or something else entirely. The confusion is understandable. Semaglutide has been available as a once-weekly injection under the Wegovy name since 2023, and Rybelsus (the tablet form) has been prescribed for type 2 diabetes in the UK since 2020. When Novo Nordisk announced an oral version for weight loss, many people assumed Rybelsus was simply being repurposed. That is not quite what happened.

The MHRA granted a brand-new marketing authorisation to Wegovy tablets on 11 June 2026, distinct from the Rybelsus licence. The weight-loss tablet uses semaglutide co-formulated with an absorption enhancer called SNAC, which allows meaningful amounts of the medicine to cross the gut wall. Rybelsus uses the same co-formulation technology but at 3 mg, 7 mg and 14 mg doses, strengths calibrated for blood-sugar management in diabetes, not for the degree of appetite suppression needed for weight loss. The Wegovy tablet tops out at 25 mg, far above Rybelsus's ceiling. So while the molecule is identical, the licensed products, the dose schedules and the intended populations are separate. You can read more about how the tablet works on our oral semaglutide overview.

Worth being clear: if a prescriber or pharmacy offers you Rybelsus for weight loss, that would be an off-label use. Wegovy tablets are the correct, on-label product for adults seeking licensed weight-management treatment with oral semaglutide.

What the Wegovy tablet dose schedule looks like, and why Rybelsus doses do not belong on it

One of the most practical questions our prescribers field is whether a patient already on Rybelsus for diabetes could simply "step up" to a higher Rybelsus dose for weight loss. The honest answer is no. The two licensed schedules are not rungs on the same ladder.

The Wegovy tablet schedule starts at 1.5 mg once daily, escalates to 4 mg, then 9 mg, and reaches a 25 mg maintenance dose, with at least a month at each level. The 3 mg, 7 mg and 14 mg strengths that Rybelsus uses do not appear in the Wegovy weight-loss schedule at all. Treating them as equivalent steps would not reflect the licensed approach. For a detailed breakdown of how the doses progress, the oral semaglutide dosing page covers the full escalation with the relevant clinical context.

How you take the Wegovy tablet also matters more than most people expect. It needs to go down first thing in the morning, before anything else, including coffee. A small amount of plain water, up to about 120 ml, is all that should go with it. Then you wait at least 30 minutes before food, other drinks or other oral medicines. This isn't a guideline to approximate; it directly affects how much semaglutide your gut absorbs. One practical note: unlike the injection pens, which live in the fridge, the tablet stores at room temperature, so it can sit on the kitchen counter next to the kettle, a small thing that genuinely helps people build the habit.

Patients already established on the 2.4 mg weekly Wegovy injection may be able to transition directly to the 25 mg tablet, subject to clinical assessment. That is a conversation for a prescriber, not a self-managed switch.

What the MHRA approval actually tells us about the oral semaglutide brand name for weight loss

The MHRA's June 2026 approval covered adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. The approval followed phase 3 trial data from the OASIS 4 study, which enrolled 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks. Average weight reduction across all participants was around 13.6%, rising to approximately 17% among those who adhered fully to the treatment, that 17% figure applies specifically to the fully-adherent group, not the overall average, and it is worth being precise about that distinction.

The most commonly reported side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation, affecting around 74% of participants taking the tablet versus 42% on placebo. Most were described as mild to moderate and settled over time, particularly as the dose increased gradually. The MHRA's approval information and the medicine's patient information leaflet carry the definitive detail on side effects and contraindications; the NHS semaglutide medicines page offers a plain-English summary. For those researching how the oral product compares with the injection, our semaglutide tablets page covers that ground.

Wegovy tablets are not currently available on the NHS. A NICE technology appraisal would be required before NHS commissioning could follow. Right now, access is through private prescription only, and any legitimate route requires a prescriber to assess your medical history, current medicines and BMI before issuing one.

How to tell a legitimate prescription route from a problematic one

Because Wegovy tablets are new and there is genuine public interest, it is worth saying plainly: these are Prescription-Only Medicines. No legitimate pharmacy or clinic can supply them without a valid UK prescription following a proper clinical assessment. The MHRA has warned repeatedly about unlicensed sellers offering weight-loss medicines online, and the same risks that apply to counterfeit injection pens apply here. If a website offers semaglutide tablets without asking about your medical history, weight or current medicines, that is a serious red flag.

Any registered online pharmacy can be verified on the GPhC pharmacy register. Look for the GPhC logo on the pharmacy's website and check the registration number independently, it takes about 30 seconds and confirms the pharmacy is regulated and inspected. At nume, our GPhC registration number is 9012878, verifiable directly at the register. Our about us page has more on how we're set up and regulated.

If you are ready to find out whether the Wegovy tablet, the Wegovy injection, or another licensed treatment suits your situation, our prescribers review consultations the same day. There is no algorithm making that call. A named, GPhC-registered Independent Prescriber reads your answers personally. If you'd like to explore your options, you can check your eligibility with a free consultation, and our FAQs cover the most common questions about how the process works. For anything specific to pricing and what a private prescription includes, the semaglutide tablets price page explains what to expect. If you are still unsure what this medicine is officially called, our page on the semaglutide tablets name explains the distinction between Wegovy and Rybelsus clearly, and if you want to compare all the products currently available, the semaglutide tablets brands page sets out what each one is licensed for.